Psychology & Sociology
In psychological disorders, monoamines play a significant role, particularly in mood regulation. These neurotransmitters include serotonin, norepinephrine, and dopamine. Imbalances in these neurotransmitters can lead to disorders such as depression, bipolar disorder, and schizophrenia.
Clinical depression is characterized by long, repeated periods of abnormally strong emotions that interfere with day-to-day life. The monoamine hypothesis links depression to low levels of serotonin, norepinephrine, and dopamine. Treatments for depression include monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs). Bipolar disorder is marked by alternating periods of depression and mania, with low monoamine levels during depressive episodes and higher levels during manic episodes. Schizophrenia, characterized by detachment from reality, is associated with an overabundance or oversensitivity to dopamine, particularly in the basal ganglia. Schizophrenia is typically treated with neuroleptics, which inhibit dopamine.
Lesson Outline
<ul> <li>Introduction to monoamines and their significance in psychological disorders <ul> <li>Three key monoamines: serotonin, norepinephrine, and dopamine</li> </ul> </li> <li>Clinical depression <ul> <li>Monoamine hypothesis: low levels of monoamines cause depression</li> <li>Antidepressant drugs: MAOIs and SSRIs <ul> <li>MAOIs: inhibit monoamine oxidase, preventing the breakdown of monoamines</li> <li>SSRIs: block serotonin reuptake, increasing serotonin levels in the synapse</li> </ul> </li> <li>Other biological markers of depression: elevated glucocorticoids and increased activity in the amygdala</li> </ul> </li> <li>Bipolar disorder <ul> <li>Alternating periods of depression and mania</li> <li>Depressive phase: drop in monoamine levels</li> <li>Manic phase: spike in serotonin and norepinephrine levels (evidence for dopamine increase as well)</li> <li>Treatment: combination of antidepressants and mood stabilizers</li> </ul> </li> <li>Schizophrenia <ul> <li>Detachment from reality, including delusions, hallucinations, and disorganized thoughts and behaviors</li> <li>Overabundance of dopamine or oversensitivity to dopamine</li> <li>Treatment: neuroleptics (antipsychotics), which inhibit dopamine</li> </ul> </li> </ul>
Don't stop here!
Get access to 51 more Psychology & Sociology lessons & 8 more full MCAT courses with one subscription!
FAQs
The biological basis of psychological disorders is rooted in the brain's structure, neurochemistry, and genetics. Abnormalities in neurotransmitter systems, such as serotonin, norepinephrine, and dopamine, have been found in people with disorders such as clinical depression, bipolar disorder, and schizophrenia. Moreover, research shows that genetic factors can increase the risk of developing specific psychological disorders.
Neurotransmitters are chemical messengers involved in the communication between brain cells. Serotonin, norepinephrine, and dopamine play a critical role in regulating mood, motivation, pleasure, and reward. Imbalances in these neurotransmitters can lead to the development of psychological disorders. For example, low levels of serotonin and norepinephrine have been linked to clinical depression, while imbalances in dopamine may contribute to bipolar disorder and schizophrenia.
Monoamines, a class of neurotransmitters that includes serotonin, norepinephrine, and dopamine, have been implicated in various psychological disorders. Abnormalities in the function or availability of these monoamines can disrupt the normal balance of neural activity and contribute to the development of disorders such as clinical depression, bipolar disorder, and schizophrenia. The monoamine hypothesis suggests that these imbalances may result from genetic predisposition, environmental factors, or a combination of both.
Genetic factors play a significant role in the development of psychological disorders, as many of these conditions tend to run in families. Research has identified specific genes that are associated with an increased risk for disorders such as clinical depression, bipolar disorder, and schizophrenia. These genes may influence the function or availability of neurotransmitters like serotonin, norepinephrine, and dopamine. Additionally, gene-environment interactions can also contribute to the development of psychological disorders, with environmental factors potentially triggering the onset of symptoms in genetically susceptible individuals.
There are several treatments for psychological disorders that target the biological basis by attempting to restore normal neurotransmitter function. Antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), work by increasing the availability of these neurotransmitters in the brain. Mood stabilizers are used to treat bipolar disorder by regulating dopamine and other neurotransmitter systems. Antipsychotic medications help manage schizophrenia by blocking or modulating specific dopamine receptors. Moreover, other biological treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS), which aim to treat psychological disorders by directly modulating brain activity.
MCAT® is a registered trademark of the Association of American Medical Colleges. The United States Medical Licensing Examination (USMLE®) is a joint program of the Federation of State Medical Boards (FSMB®) and National Board of Medical Examiners (NBME®). NAPLEX® is a registered trademark of the National Association of Boards of Pharmacy. PANCE© is a registered trademark of the National Commission on Certification of Physician Assistants. NCLEX® is a registered trademark and service mark of the National Council of State Boards of Nursing, Inc. None of the trademark holders are endorsed by nor affiliated with Sketchy or this website.
